Streetbeat News

LRMR

Larimar Therapeutics, Inc.

https://www.larimartx.com

Industry

Biotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Open

9.20

Mkt cap

569M

Volume

577K

High

9.33

P/E Ratio

-6.91

52-wk high

13.68

Low

8.80

Div yield

N/A

52-wk low

2.18

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating for Larimar Therapeutics (NASDAQ:LRMR) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 9:42 am

Larimar Therapeutics shares rose following the announcement of better-than-expected Q3 EPS results.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 3:34 pm

Larimar Therapeutics reported a Q3 2024 GAAP EPS of $(0.24), beating the analyst estimate of $(0.39). The company has $203.7M in cash and equivalents.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:21 am

Oppenheimer has initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Outperform rating and a $26 price target, citing the potential of its lead drug, Nomlabofusp, to transform treatment for Friedreich’s ataxia. The drug targets frataxin deficiency, a key factor in the disease. Larimar plans to expand into pediatric populations and pursue accelerated FDA approval. The company aims for a U.S. launch in 2027 and a European launch in 2028, with projected global revenues of $1.2 billion by 2030. The stock is currently up 2.56% at $7.61.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 6:59 pm

Larimar Therapeutics shares rose after Oppenheimer initiated coverage with an Outperform rating and a $26 price target.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 4:23 pm

Oppenheimer has initiated coverage on Larimar Therapeutics with an Outperform rating and set a price target of $26.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 9:09 am

Larimar Therapeutics shares rose after Wedbush initiated coverage with an Outperform rating and set a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:01 pm

Wedbush analyst Laura Chico has initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Outperform rating and set a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 1:49 pm

HC Wainwright & Co. has initiated coverage on Larimar Therapeutics with a Buy rating and set a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:12 am

Larimar Therapeutics shares rose following the announcement that data from its Nomlabofusp Phase 1 and Phase 2 studies will be presented at the International Congress for Ataxia Research.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 3:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.